Literature DB >> 11719911

Cognitive therapy for depression.

J Scott1.   

Abstract

There is considerable empirical support for the use of cognitive therapy in the treatment of mild to moderately severe acute major depression. More recent research has focused on the utility of this approach in severe or chronic depressive disorders, in relapse prevention and also on the potential benefits of combining cognitive therapy with medication. This paper attempts to clarify the empirical data on these important issues in order to identify further the role of cognitive therapy in day-to-day clinical practice. It also provides an overview of findings regarding predictors of response to cognitive therapy and the possible mediators of its effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11719911     DOI: 10.1093/bmb/57.1.101

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  4 in total

1.  The effect of a cognitive and a physical stress-reducing programme on psychological complaints.

Authors:  Willem Van Rhenen; Roland W B Blonk; Jac J L van der Klink; Frank J H van Dijk; Wilmar B Schaufeli
Journal:  Int Arch Occup Environ Health       Date:  2005-03-11       Impact factor: 3.015

2.  Medical patients' attitudes toward emotional problems and their treatment. What do they really want?

Authors:  Bernd Löwe; Ute Schulz; Kerstin Gräfe; Stefanie Wilke
Journal:  J Gen Intern Med       Date:  2006-01       Impact factor: 5.128

3.  Patients' written life stories: a gateway for understanding.

Authors:  Benny Ehrenreich; Jens Hilden; Kirsti Malterud
Journal:  Scand J Prim Health Care       Date:  2007-03       Impact factor: 2.581

4.  The clinical and cost effectiveness of cognitive behavioural therapy plus treatment as usual for the treatment of depression in advanced cancer (CanTalk): study protocol for a randomised controlled trial.

Authors:  Marc Serfaty; Michael King; Irwin Nazareth; Adrian Tookman; John Wood; Anna Gola; Trefor Aspden; Kathryn Mannix; Sarah Davis; Stirling Moorey; Louise Jones
Journal:  Trials       Date:  2016-02-29       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.